Alberry M, Shyam D, Thompson D P02.14: Prenatal diagnosis of Hb H hydrops fetalis caused by haemoglobin Adana. Ultrasound Obstet Gynecol. 2013; 42:(s1)

Ansari SH, Lassi ZS, Ali SM, Adil SO, Shamsi TS Hydroxyurea for ß-thalassaemia major. Cochrane Database Syst Rev. 2016; 1

Boe GP Thalassaemias. Journal of Continuing Education Topics & Issues. 2013; 15:(1)17-18

Borgna-Pignatti C, Marsella M Iron chelation in thalassaemia major. Clin Ther. 2015; 37:(12)2866-77

Chakrabarti S, Nayek H, Kanrar P, Mondal S An observational study on thalassaemia in pregnancy and its effects with a view to find measures for reduction of its complications and improvement of maternal and perinatal outcome. Journal of Evolution of Medical and Dental Sciences. 2014; 3:(5)1149-56

Chowdary P, Adamidou D, Riddell A, Aghighi S, Griffioen A, Priest P Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring. Br J Haematol. 2015; 168:(5)719-27

Chu NL, Wu Z, Zhang XH, Fang SP, Wang WJ, Cheng YL Molecular mechanism of yisui shengxue granule, a complex chinese medicine, on thalassaemia patients suffering from hemolysis and anemia of erythrocytes. Evidence-Based Complementary and Alternative Medicine. 2014; 2014:1-11

Costa E(ed). UAE: Bentham Science; 2013

Davis B Fertility and pregnancy in thalassaemia and sickle cell disease. The UK guidelines. Thalassaemia Reports. 2014; 4:(3)

de Dreuzy E, Bhukhai K, Leboulch P, Payen E Current and future alternative therapies for beta-thalassaemia major. Biometrical Journal. Biometrische Zeitschrift. 2016; 39:(1)24-38

Egitto EA, Grogan S Does folic acid supplementation have a role in the treatment of anemia associated with beta thalassemia?. Evidence Based Practice. 2016; 19:(2)

Eissa AA, Tuck SM Sickle cell disease and β-thalassaemia major in pregnancy. The Obstetrician & Gynaecologist. 2013; 15:(2)71-8

El Sayed SM, Abou-Taleb A, Mahmoud HS, Baghdadi H, Maria RA, Ahmed NS, Nabo MMH Percutaneous excretion of iron and ferritin (through Al-hijamah) as a novel treatment for iron overload in beta-thalassaemia major, hemochromatosis and sideroblastic anemia. Medical Hypotheses. 2014a; 83:(2)238-46

El Sayed SM, Al-quliti A-S, Mahmoud HS, Baghdadi H, Maria RA, Nabo MMH, Hefny A Therapeutic benefits of Al-hijamah: in light of modern medicine and prophetic medicine. American Journal of Medical and Biological Research. 2014b; 2:(2)46-71

Elalfy MS, Saber MM, Adly AA, Ismail EA, Tarif M, Ibrahim F, Elalfy OM Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassaemia major patients: efficacy and safety in relation to tissue iron overload. Eur J Haematol. 2016; 96:(3)318-26

Fibach E, Rachmilewitz EA Does erythropoietin have a role in the treatment of β-hemoglobinopathies?. Hematol Oncol Clin North Am. 2014; 28:(2)249-63

Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2013; 21:(8)

Hall HG, McKenna LG, Griffiths DL Midwives’ support for Complementary and Alternative Medicine: a literature review. Women Birth. 2012; 25:(1)4-12

Hanprasertpong T, Kor-anantakul O, Leetanaporn R, Suntharasaj T, Suwanrath C, Pruksanusak N, Pranpanus S Pregnancy outcomes amongst thalassaemia traits. Arch Gynecol Obstet. 2013; 288:(5)1051-4

He S, Zheng C, Meng D, Chen R, Zhang Q, Tian X, Chen S Hb H Hydrops Fetalis Syndrome Caused by Association of the − − SEA Deletion and Hb Constant Spring (HBA2 : c.427T > C) Mutation in a Chinese Family. Hemoglobin. 2015; 39:(3)216-9

Higgs DR, Engel JD, Stamatoyannopoulos G Thalassaemia. Lancet. 2012; 379:(9813)373-83

Inati A, Noureldine MA, Mansour A, Abbas HA Endocrine and bone complications in β-thalassaemia intermedia: current understanding and treatment. Biomed Res Int. 2015; 2015

Koh MB, Lao ZT, Rhodes E Managing haematological disorders during pregnancy. Best Pract Res Clin Obstet Gynaecol. 2013; 27:(6)855-65

Leung TY, Lao TT Thalassaemia in pregnancy. Best Practice & Research. Clin Obstet Gynaecol. 2012; 26:(1)37-51

Li MJ, Peng SS, Lu MY, Chang HH, Yang YL, Jou ST, Lin DT, Lin KH Diabetes mellitus in patients with thalassaemia major. Pediatr Blood Cancer. 2014; 61:(1)20-4

Machin A Thalassaemia. Innovait: Education and Inspiration For General Practice. 2014;

Morton MR, Hague WM A woman with hypertension. Case Studies in Assisted Reproduction. Common and Uncommon Presentations. 2015; 7-11

Noori N, Keshavarz K Comparison of captopril with enalapril on improvement of systolic and diastolic heart functions in asymptomatic patients over 10 years old with beta-thalassaemia major. Iranian Journal of Medical Sciences. 2015; 33:(4)235-9

Patterson JA, Roberts CL, Bowen JR, Irving DO, Isbister JP, Morris JM, Ford JB Blood transfusion during pregnancy, birth, and the postnatal period. Obstet Gynecol. 2014; 123:(1)126-33

Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013; 381:(9861)142-51

Pillai VG DVT and pregnancy.(eds.). London: Springer; 2016

Richardson DP Developing the Right Public Health Strategies for Folic Acid and Reduction of Risk of Neural Tube Defects (NTDs) in the United Kingdom. European Journal of Nutrition & Food Safety. 2015; 5:(4)242-9

Rund D Thalassaemia 2016: Modern medicine battles an ancient disease. Am J Hematol. 2016; 91:(1)15-21

Guidelines for the clinical care of patients with thalassaemia in Canada. Anemia Institute for Research and Education & Thalassaemia Foundation of Canada. 2009. (accessed 15 July 2016)

Sienas L, Wong T, Collins R, Smith J Contemporary uses of erythropoietin in pregnancy: a literature review. Obstet Gynecol Surv. 2013; 68:(8)594-602

Thompson AA, Kim HY, Singer ST, Vichinsky E, Eile J, Yamashita R, Giardina PJ, Olivieri N, Parmar N, Trachtenberg F, Neufeld EJ, Kwiatkowski JL Pregnancy outcomes in women with thalassaemia in North America and the United Kingdom. Am J Hematol. 2013; 88:(9)771-3

Vichinsky EP Changing patterns of thalassaemia worldwide. Ann N Y Acad Sci. 2005; 1054:(1)18-24

Voskaridou E, Balassopoulou A, Boutou E, Komninaka V, Christoulas D, Dimopoulou M, Delaki EE, Loukopoulos D, Terpos E Pregnancy in beta-thalassaemia intermedia: 20-year experience of a Greek thalassaemia center. Eur J Haematol. 2014; 93:(6)492-9

Zafari M, Kosaryan M Marriage and child bearing in patients with transfusion-dependent thalassaemia major. J Obstet Gynaecol Res. 2014; 40:(8)1978-82

Thalassaemia in pregnancy: Contemporary care for a timeless disease

02 August 2016
Volume 24 · Issue 8


Globally, thalassaemia is one of the most common genetic blood disorders affecting women's ability to conceive and progress through a normal pregnancy and birth. Thalassaemia is associated with late-onset puberty, infertility due to endocrine dysfunction, growth retardation, jaundice, deformities in skeletal development and enlargement of the abdomen secondary to spleen and liver anomalies. Despite medical innovations, the management of thalassaemia remains associated with significant risk factors for women during pregnancy, birth and the postnatal period. The management of women with thalassaemia is complex, requiring a multidisciplinary approach to care as the potential for maternal and fetal complications presents risks during pregnancy and birth. Women can remain silent carriers of the disease until pregnancy induces symptomatic haematological and coagulation changes, leading to diagnosis of thalassaemia.

Thalassaemia is one of the most common genetic blood disorders affecting women's ability to conceive and progress through a normal pregnancy and birth (Hanprasertpong et al, 2013). Currently, there are approximately 269 million carriers of thalassaemia worldwide; the condition affects approximately 4.4 of every 10 000 live births throughout the world, and a predicted 900 000 births will have clinically significant thalassaemia disorders expected to occur by 2025 (Vichinsky, 2005). Initially thought to be a disease originating from Mediterranean regions, migration of populations throughout Asia and Africa has seen the prevalence of thalassaemia spread to countries previously considered low in rates of diagnosed cases (Piel et al, 2013). Thalassaemia encompasses a group of autosomal-recessive conditions involving the abnormal production of red blood cells and reduced haemoglobin levels (Machin, 2014). The disease presents with various physical symptoms depending on the acuity of the condition, and is divided into three diagnostic groups determined by the level of severity of symptoms and degree of systemic involvement in the condition (Chakrabarti et al, 2014). These groups categorise thalassaemia into minor, major and intermedia conditions, classifying a range from asymptomatic carriers (thalassaemia minor) to infusion-dependent people with reduced prognosis and early morbidity (thalassaemia major). The disease simplified is a mutation in erythropoiesis caused by reduced or absent alpha and beta globin chains that combine to form a red blood cell (Voskaridou et al, 2014). Haemoglobinopathies occur, which cause the onset of thalassaemia traits.

Register now to continue reading

Thank you for visiting British Journal of Midwifery and reading some of our peer-reviewed resources for midwives. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to our clinical or professional articles

  • New content and clinical newsletter updates each month